Pelcitoclax

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NamePelcitoclax
Drug Alias NamepalcitoclaxBM-1252APG-1252APG 1252 12A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-X inhibitorsApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-XApoptosis regulator Bcl-2
Therapy Area/IndicationsSolid tumoursPrimary MyelofibrosisEndometrial Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Ascentage Pharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAscentage Pharma Group IncNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[4] 
Inactive CompaniesN/A
Active IndicationsEndometrial NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsSolid tumoursPrimary MyelofibrosisSmall Cell Lung Carcinoma +[5] 

Other Information

ATC CodeN/A
Related LinksN/A